Oral anticoagulants found to be more effective and cost-effective than heparin for cancer-associated thrombosis

A cost-effectiveness analysis comparing direct oral anticoagulants (DOACs) to low-molecular-weight heparin (LMWH) found that DOACs.

Extending anti-clotting treatment after distal deep vein thrombosis could reduce further clot risk

Giving the anti-clotting drug rivaroxaban to patients for 12 weeks instead of the usual six.